Vertex Pharmaceuticals's earnings have been declining at an average annual rate of -6.3%, while the Biotechs industry saw earnings growing at 15.1% annually. Revenues have been growing at an average rate of 12.3% per year. Vertex Pharmaceuticals's return on equity is 21.2%, and it has net margins of 32.9%.
Key information
-6.27%
Earnings growth rate
-6.10%
EPS growth rate
Biotechs Industry Growth
12.91%
Revenue growth rate
12.34%
Return on equity
21.18%
Net Margin
32.94%
Next Earnings Update
04 May 2026
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Vertex Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
BMV:VRTX * Revenue, expenses and earnings (USD Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Dec 25
12,001
3,953
1,753
0
30 Sep 25
11,723
3,675
1,644
0
30 Jun 25
11,419
3,638
1,570
0
31 Mar 25
11,100
-989
1,518
0
31 Dec 24
11,020
-536
1,464
0
30 Sep 24
10,626
-480
1,456
0
30 Jun 24
10,337
-490
1,348
0
31 Mar 24
10,185
4,019
1,238
0
31 Dec 23
9,869
3,620
1,137
0
30 Sep 23
9,654
3,470
1,035
0
30 Jun 23
9,505
3,365
1,018
0
31 Mar 23
9,208
3,260
971
0
31 Dec 22
8,931
3,322
945
0
30 Sep 22
8,701
3,273
933
0
30 Jun 22
8,350
3,195
884
0
31 Mar 22
7,948
2,451
863
0
31 Dec 21
7,574
2,342
840
0
30 Sep 21
7,130
2,176
797
0
30 Jun 21
6,684
1,992
783
0
31 Mar 21
6,415
2,762
780
0
31 Dec 20
6,206
2,712
771
0
30 Sep 20
5,991
2,691
754
0
30 Jun 20
5,403
2,081
729
0
31 Mar 20
4,819
1,511
694
0
31 Dec 19
4,163
1,177
659
0
30 Sep 19
3,620
2,144
616
0
30 Jun 19
3,454
2,215
594
0
31 Mar 19
3,265
2,155
575
0
31 Dec 18
3,048
2,096
558
0
30 Sep 18
2,829
647
539
0
30 Jun 18
2,623
415
523
0
31 Mar 18
2,415
226
513
0
31 Dec 17
2,489
263
496
0
30 Sep 17
2,296
196
471
0
30 Jun 17
2,131
259
457
0
31 Mar 17
2,019
177
441
0
31 Dec 16
1,702
-112
433
0
30 Sep 16
1,661
-219
419
0
30 Jun 16
1,557
-275
413
0
31 Mar 16
1,292
-399
396
0
31 Dec 15
1,032
-556
377
0
30 Sep 15
759
-659
359
0
30 Jun 15
628
-734
334
0
Quality Earnings: VRTX * has high quality earnings.
Growing Profit Margin: VRTX * became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VRTX *'s earnings have declined by 6.3% per year over the past 5 years.
Accelerating Growth: VRTX * has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: VRTX * has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (11.6%).
Return on Equity
High ROE: VRTX *'s Return on Equity (21.2%) is considered high.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/04/30 04:38
End of Day Share Price
2026/04/30 00:00
Earnings
2025/12/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vertex Pharmaceuticals Incorporated is covered by 58 analysts. 29 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.